Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors
Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
1. A pharmaceutical composition comprising:
a small molecule prolactin receptor (PRLR) inhibitor according to Formula II or a pharmaceutical salt thereof; and
at least one pharmaceutically acceptable carrier,
wherein Formula II is structurally depicted as:
and wherein:
R 1 is selected from —CY 3 , linear or cyclic alkyl, halogen, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and H;
X is selected from —NH 2 , halogen, —OH, —SH, —NO 2 , —COOH, —SO 3 H, and —SO 2 NH 2 ;
n is 0 or an integer between 1 and 10; and
each Y is independently H or halogen selected from Cl, Br, F, and I.
2. The pharmaceutical composition according to claim 1 , wherein R 1 is para and selected from —CY 3 , halogen and H, and n is 0, 1 or 2.
3. The pharmaceutical composition according to claim 1 , wherein the small molecule PRLR inhibitor is a compound according to Formula II and structurally depicted as:
4. The pharmaceutical composition according to claim 1 , formulated as an injectable solution or as an oral dosing form.
5. The pharmaceutical composition according to claim 4 , wherein the molar concentration of inhibitor is up to 10 μM, up to 5 μM, between 1 μM and 10 μM, between 5 μM and 10 μM or between 1 μM and 5 μM.